NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/08/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization38.49 mln
Float8.58 mln
Earnings Date08/17/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
22.75
Transformational upside
Relative Strength
17
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-77.56
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Atossa Therapeutics is a Seattle-based company focused on developing new treatments for breast cancer and other conditions that currently lack effective options. Its most advanced drug candidate is oral endoxifen, a compound derived from the widely used cancer drug tamoxifen, which is currently being tested in Phase II clinical trials for both treating and preventing breast cancer. The company is also exploring immune-based therapies as part of its broader research efforts. Founded in 2008, Atossa has been working to bring meaningful new options to patients who need them most.
